194 related articles for article (PubMed ID: 34589576)
1. m
Ji F; Lu Y; Chen S; Lin X; Yu Y; Zhu Y; Luo X
Mol Ther Oncolytics; 2021 Sep; 22():574-581. PubMed ID: 34589576
[TBL] [Abstract][Full Text] [Related]
2. N
Ren Z; Hu Y; Sun J; Kang Y; Li G; Zhao H
Bioengineered; 2022 Apr; 13(4):7963-7973. PubMed ID: 35356854
[TBL] [Abstract][Full Text] [Related]
3. Silencing of long non-coding RNA FOXD2-AS1 inhibits the progression of gallbladder cancer by mediating methylation of MLH1.
Gao J; Dai C; Yu X; Yin XB; Liao WJ; Huang Y; Zhou F
Gene Ther; 2021 Jun; 28(6):306-318. PubMed ID: 32917950
[TBL] [Abstract][Full Text] [Related]
4. Long Noncoding RNA
Dou X; Zhou Q; Wen M; Xu J; Zhu Y; Zhang S; Xu X
Front Pharmacol; 2019; 10():1700. PubMed ID: 32082174
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of the long noncoding RNA FOXD2-AS1 promotes carcinogenesis by epigenetically silencing EphB3 through EZH2 and LSD1, and predicts poor prognosis in gastric cancer.
Xu TP; Wang WY; Ma P; Shuai Y; Zhao K; Wang YF; Li W; Xia R; Chen WM; Zhang EB; Shu YQ
Oncogene; 2018 Sep; 37(36):5020-5036. PubMed ID: 29789713
[TBL] [Abstract][Full Text] [Related]
6. HIF-1α induced long noncoding RNA FOXD2-AS1 promotes the osteosarcoma through repressing p21.
Ren Z; Hu Y; Li G; Kang Y; Liu Y; Zhao H
Biomed Pharmacother; 2019 Sep; 117():109104. PubMed ID: 31228799
[TBL] [Abstract][Full Text] [Related]
7.
Shangguan W; Lv X; Tian N
Korean J Physiol Pharmacol; 2019 Nov; 23(6):475-482. PubMed ID: 31680769
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA FOXD2-AS1 promotes glioma malignancy and tumorigenesis via targeting miR-185-5p/CCND2 axis.
Shen F; Chang H; Gao G; Zhang B; Li X; Jin B
J Cell Biochem; 2019 Jun; 120(6):9324-9336. PubMed ID: 30520141
[TBL] [Abstract][Full Text] [Related]
9. Oncogenicity of lncRNA FOXD2-AS1 and its molecular mechanisms in human cancers.
Hu Q; Tai S; Wang J
Pathol Res Pract; 2019 May; 215(5):843-848. PubMed ID: 30723052
[TBL] [Abstract][Full Text] [Related]
10. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.
Lei T; Zhu X; Zhu K; Jia F; Li S
Cancer Biol Ther; 2019; 20(7):1007-1016. PubMed ID: 30929558
[TBL] [Abstract][Full Text] [Related]
11. LncRNA FOXD2-AS1 accelerates the progression of cervical cancer via downregulating CDX1.
Chen DZ; Wang TF; Dai WC; Xu X; Chen PF
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10234-10240. PubMed ID: 31841177
[TBL] [Abstract][Full Text] [Related]
12. LncRNA FOXD2-AS1 knockdown inhibits the resistance of human osteosarcoma cells to cisplatin by inhibiting miR-143 expression.
Zhang QQ; Xu SL; Ding C; Ma CC; Yuan TS; Hua CC; Wang XH
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):678-686. PubMed ID: 33577022
[TBL] [Abstract][Full Text] [Related]
13. LncRNA FOXD2-AS1 Functions as a Competing Endogenous RNA to Regulate TERT Expression by Sponging miR-7-5p in Thyroid Cancer.
Liu X; Fu Q; Li S; Liang N; Li F; Li C; Sui C; Dionigi G; Sun H
Front Endocrinol (Lausanne); 2019; 10():207. PubMed ID: 31024447
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of FOXD2-AS1 enhances proliferation and impairs differentiation of glioma stem cells by activating the NOTCH pathway via TAF-1.
Wang Y; Cheng Y; Yang Q; Kuang L; Liu G
J Cell Mol Med; 2022 May; 26(9):2620-2632. PubMed ID: 35419917
[TBL] [Abstract][Full Text] [Related]
15. Silencing lncRNA FOXD2-AS1 inhibits proliferation, migration, invasion and drug resistance of drug-resistant glioma cells and promotes their apoptosis via microRNA-98-5p/CPEB4 axis.
Gu N; Wang X; Di Z; Xiong J; Ma Y; Yan Y; Qian Y; Zhang Q; Yu J
Aging (Albany NY); 2019 Nov; 11(22):10266-10283. PubMed ID: 31770107
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA FOXD2-AS1 promotes proliferation, migration and invasion of ovarian cancer cells via regulating the expression of miR-4492.
Gao J; Liu F; Zhao X; Zhang P
Exp Ther Med; 2021 Apr; 21(4):307. PubMed ID: 33717250
[TBL] [Abstract][Full Text] [Related]
17. Highly expressed long non-coding RNA FOXD2-AS1 promotes non-small cell lung cancer progression via Wnt/β-catenin signaling.
Rong L; Zhao R; Lu J
Biochem Biophys Res Commun; 2017 Mar; 484(3):586-591. PubMed ID: 28132805
[TBL] [Abstract][Full Text] [Related]
18. Silence of FOXD2-AS1 inhibited the proliferation and invasion of esophagus cells by regulating miR-145-5p/CDK6 axis.
Shi W; Gao Z; Song J; Wang W
Histol Histopathol; 2020 Sep; 35(9):1013-1021. PubMed ID: 32524576
[TBL] [Abstract][Full Text] [Related]
19. m
Xue L; Li J; Lin Y; Liu D; Yang Q; Jian J; Peng J
J Cell Physiol; 2021 Apr; 236(4):2649-2658. PubMed ID: 32892348
[TBL] [Abstract][Full Text] [Related]
20. LncRNA FOXD2-AS1 accelerates the papillary thyroid cancer progression through regulating the miR-485-5p/KLK7 axis.
Zhang Y; Hu J; Zhou W; Gao H
J Cell Biochem; 2019 May; 120(5):7952-7961. PubMed ID: 30456805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
